Time filter

Source Type

Sun W.,College of Logistics | Deng C.,College of Logistics | Hao H.,College of Logistics | Kang Y.,Beijing Tiantan Biological Products | Si Y.,College of Logistics
Materials Letters | Year: 2013

A novel nano carbon network composed of multi-walled carbon nanotubes (MWCNTs) and acetylene black (AB) were used as coating materials for LiFePO 4. LiFePO4 particles were connected by multi-walled carbon nanotubes to form a three-dimensional network coating and acetylene black repaired the incomplete carbon coating areas. This nano network structure can improve cyclic performance of the cathode composite effectively. The initial discharge capacity of LiFePO4/5 wt% MWCNTs+5 wt% AB was 161.3 mAh/g at 0.2 C. Besides, the cycling performance was also improved by such kind of coating, SEM images showing the change of electrodes after cycles were also displayed. © 2012 Elsevier B.V.


News Article | November 2, 2016
Site: www.prnewswire.co.uk

RnRMarketResearch.com adds "Neutropenia - Pipeline Review, H2 2016" market research report to its store. The report provides an overview of the Neutropenia's therapeutic pipeline with comprehensive information on the therapeutic development for Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neutropenia and special features on late-stage and discontinued projects. Complete report on H2 2016 pipeline review of Neutropenia with 31 market data tables and 14 figures, spread across 93 pages is available at http://www.rnrmarketresearch.com/neutropenia-pipeline-review-h2-2016-market-report.html. Neutropenia pipeline therapeutics constitutes close to 26 molecules. Out of which approximately 26 molecules are developed by Companies. The report outlays comprehensive information on the therapeutics under development for Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Neutropenia is an abnormally low count of neutrophils, a type of white blood cell that helps fight off infections, particularly those caused by bacteria and fungi. Signs and symptoms include fevers, frequent infections, mouth ulcers, gum infections and dysuria. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 1, 3, 4, 9, 1 and 3 respectively. Furthermore, this report also reviews of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies discussed in this Neutropenia Pipeline Review, H2 2016 report include Apotex Inc., BeyondSpring Pharmaceuticals, Inc., Biogenomics Limited, Cellerant Therapeutics, Inc., Cleveland BioLabs, Inc., Coherus BioSciences, Inc., Dr. Reddy's Laboratories Limited, Eurofarma Laboratorios S.A., Ligand Pharmaceuticals, Inc., NAL Pharmaceuticals Ltd., Prolong Pharmaceuticals, LLC, Richter Gedeon Nyrt., Sandoz International GmbH, Therapeutic Proteins International, LLC, Toko Pharmaceutical Industries Co., Ltd. and USV Pvt Ltd. Drug Profiles mentioned in this research report are ACN-8337, CBLB-612, EC-18, filgrastim, LG-7455, pegfilgrastim, pegfilgrastim (recombinant), plinabulin, romyelocel-L, ST-7 and tamibarotene. Scope of this report: The report provides a snapshot of the global therapeutic landscape of Neutropenia and reviews pipeline therapeutics for Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Neutropenia therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Neutropenia. Another newly published market research report titled on Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Varicella Zoster (HHV-3) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Varicella Zoster (HHV-3) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are Astellas Pharma Inc., Beijing Minhai Biotechnology Co., Ltd, Beijing Tiantan Biological Products Co., Ltd., ContraVir Pharmaceuticals, Inc., Epiphany Biosciences Inc., Foamix Pharmaceuticals Ltd., GeneOne Life Science, Inc., GlaxoSmithKline Plc, Green Cross Corporation, Merck & Co., Inc., N & N Pharmaceuticals Inc., NAL Pharmaceuticals Ltd., NanoViricides, Inc., ReceptoPharm, Inc., Sinovac Biotech Ltd., SK Chemicals Co., Ltd., TSRL, Inc., XBiotech Inc and Zydus Cadila Healthcare Limited. Varicella Zoster (HHV-3) Infections Pipeline market research report of 172 pages is available at http://www.rnrmarketresearch.com/varicella-zoster-hhv-3-infections-pipeline-review-h2-2016-market-report.html. RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers.


Report offers a brief overview about German measles disease and its therapeutic development. It is an infectious disease caused by a virus called “Rubella.” This directly infects the skin and lymph nodes. The main symptom is a pink spotty rash that starts from the face and spreads to the arms & chest. Albany, NY, November 26, 2016 --( Request for Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=873444 The report offers a brief overview about German measles disease and its therapeutic development. It is an infectious disease caused by a virus called “Rubella.” This directly infects the skin and lymph nodes. The main symptom is a pink spotty rash that starts from the face and spreads to the arms & chest. Other symptoms include mild fever, headaches, swollen glands, joint pain and red eyes. German measles is highly infectious to child bearing women during the first trimester of pregnancy. This disease can even cause miscarriage or birth defects. It is generally transmitted by airborne droplets when an infected person coughs or sneezes. The report further highlights greater focus on effective drug treatment of Rubella. In addition, increasing R&D programs for development of new therapies to successfully treat the disease is expected to favor the market in the near future. According to the study, German measles is extremely rare in the United States. Most of the cases occur in people who live in countries that don’t offer routine immunization against Rubella. Generally, mainstream medicine doesn't have a specific treatment for German measles as it goes away within a week and the mild symptoms can be managed with bed rest and medicines. But the doctors advise pregnant women for virus vaccine immunization to avoid acquiring German measles. A vaccine named measles-mumps-rubella (MMR) can be used to effectively prevent it. The rubella vaccine was introduced in the late 1960s and due to this vaccine the incidence of German measles has significantly declined. Also, a mixture of proteins in the blood called “Gamma globulin” is offered to prevent the disease. The Rubella pipeline guide also review the key players involved in therapeutic development for this infection and also features dormant and discontinued projects. Some of the key players are- Beijing Minhai Biotechnology Co. Biological E. Limited Beijing Tiantan Biological Products GlaxoSmithKline Plc Daiichi Sankyo Company Indian Immunologicals Limited Prometheon Pharma Sinovac Biotech Ltd. Zydus Cadila Healthcare Limited Browse Full Report with TOC: http://www.marketresearchhub.com/report/rubella-german-measles-pipeline-review-h2-2016-report.html The guide also helps in identifying emerging players in the market along with their portfolios which enhances decision making capabilities for the new entrants. About Us Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps. MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients. Contact Us 90 State Street Albany, NY 12207, United States Toll Free : 866-997-4948 (US-Canada) Tel : +1-518-621-2074 Email : press@marketresearchhub.com Website : http://www.marketresearchhub.com Albany, NY, November 26, 2016 --( PR.com )-- The latest pipeline guide on pharmaceutical and healthcare disease by Global Market Direct has been launched and added to Market Research Hub’s vast partfolio of research reports. The report is titled as “Rubella (German Measles) - Pipeline Review, H2 2016.” This guide evaluates Rubella’s therapeutics development based on mechanism of action (MoA), drug target, monotherapy products, combination products, route of administration (RoA) and molecule type.Request for Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=873444The report offers a brief overview about German measles disease and its therapeutic development. It is an infectious disease caused by a virus called “Rubella.” This directly infects the skin and lymph nodes. The main symptom is a pink spotty rash that starts from the face and spreads to the arms & chest. Other symptoms include mild fever, headaches, swollen glands, joint pain and red eyes. German measles is highly infectious to child bearing women during the first trimester of pregnancy. This disease can even cause miscarriage or birth defects. It is generally transmitted by airborne droplets when an infected person coughs or sneezes.The report further highlights greater focus on effective drug treatment of Rubella. In addition, increasing R&D programs for development of new therapies to successfully treat the disease is expected to favor the market in the near future. According to the study, German measles is extremely rare in the United States. Most of the cases occur in people who live in countries that don’t offer routine immunization against Rubella. Generally, mainstream medicine doesn't have a specific treatment for German measles as it goes away within a week and the mild symptoms can be managed with bed rest and medicines. But the doctors advise pregnant women for virus vaccine immunization to avoid acquiring German measles. A vaccine named measles-mumps-rubella (MMR) can be used to effectively prevent it. The rubella vaccine was introduced in the late 1960s and due to this vaccine the incidence of German measles has significantly declined. Also, a mixture of proteins in the blood called “Gamma globulin” is offered to prevent the disease.The Rubella pipeline guide also review the key players involved in therapeutic development for this infection and also features dormant and discontinued projects. Some of the key players are-Beijing Minhai Biotechnology Co.Biological E. LimitedBeijing Tiantan Biological ProductsGlaxoSmithKline PlcDaiichi Sankyo CompanyIndian Immunologicals LimitedPrometheon PharmaSinovac Biotech Ltd.Zydus Cadila Healthcare LimitedBrowse Full Report with TOC: http://www.marketresearchhub.com/report/rubella-german-measles-pipeline-review-h2-2016-report.htmlThe guide also helps in identifying emerging players in the market along with their portfolios which enhances decision making capabilities for the new entrants.About UsMarket Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.Contact Us90 State StreetAlbany, NY 12207,United StatesToll Free : 866-997-4948 (US-Canada)Tel : +1-518-621-2074Email : press@marketresearchhub.comWebsite : http://www.marketresearchhub.com Click here to view the list of recent Press Releases from Market Research Hub


Wang X.,Beijing Tiantan Biological Products
Chinese Journal of Biologicals | Year: 2012

Objective: To compare the breakage effects of recombinant Hansenula polymorpha (HP) cells for expression of hepatitis B surface antigen (HBsAg) by bead-milling, low-temperature high-pressure homogenization and Yeast Buster cell lysate treatment. Methods: Recombinant HP cells for expression of HBsAg were broken by bead-milling, low-temperature high-pressure homogenization and Yeast Buster cell lysate treatment respectively, using recombinant Saccharomyces cerevisiae cells as control. The breakage rates of cells and the releases of protein and HBsAg were determined, based on which the effects of three methods were compared. Results: The components in either jars or beads were abraded into the cells broken by bead-milling. Agate jars and zirconia beads produced fewer impurities, by which the breakage rate of HP cells was only about 60%. The highest protein content of HP cells broken by bead-milling with agate jars and glass beads was 2.71 mg/ml, while the highest release of HBsAg was 180.04 μg/ml. The breakage rate of recombinant HP cells by low-temperature high-pressure homogenization was 71.18% at most, while the highest protein content was 6.72 mg/ml, and the highest release of HBsAg was 350.63 μg/ml. However, the breakage rate of HP cells by Yeast Buster cell lysate was 60.30%, while significant differences were observed in protein contents and HBsAg releases in the cells broken for various times. Conclusion: Compared with bead-milling and Yeast Buster cell lysate treatment, low-temperature high pressure homogenization is more suitable for breakage of recombinant HP cells for expression of HBsAg.


Liu Y.-W.,Beijing Tiantan Biological Products
Chinese Journal of Biologicals | Year: 2012

Objective: To evaluate the removal effect of endotoxin in purification process of HBsAg expressed in recombinant Hansenula polymorpha. Methods: The endotoxin contents in HBsAg expressed in recombinant H. polymorpha in steps of cell disruption, microfiltration, ultra-filtration, adsorption with silica gel, chromatography and sterile filtration in small and middle scales as well as pilot purification process were determined by limulus amoebocyte lysate (LAL) test, using those in the HBsAg expressed in recombinant Saccharomyces cerevisiae as control, based on which the removal rate of endotoxin was calculated, and the relationship between purification procedure and the removal rate was analyzed. Results: During the purification of HBsAg expressed in recombinant H. polymorpha, the endotoxin content of samples decreased from 241 EU/ml in step of cell disruption to less than 1.0 EU/ml in step of sterile filtration. The removal rates of endotoxin in samples in steps of microfiltration and ultra-filtration were 56% and 86% respectively, accounting for more than 90% of removal rate of endotoxin in the whole purification process. Conclusion: The steps of microfiltration, ultra-filtration and hydrophobic chromatography in purification process were effective for removal of endotoxin, of which ultra-filtration was the most effective. It provided technical parameters and an experimental basis for study on removal of endotoxin in purification process.


Ye X.,Beijing Tiantan Biological Products
Chinese Journal of Biologicals | Year: 2012

Objective: To analyze the characteristics of suspected adverse events following immunization (AEFI) in Harbin City, China in 2011 and evaluate the AEFI surveillance system. Methods: A descriptive analysis was performed on the data on AEFI reported in Information Management System of AEFI in Harbin in 2011. Results: A total of 188 cases of AEFI were reported in Harbin in 2011, most (86.7%) of which were general reactions. However, 72.9% of the cases were reported from July to December. Most of the cases were observed in the infants at ages of not more than 1 year and more than 1 year but not more than 2 years, which accounted for 42.0% and 36.2% of the total number respectively. A portion of 49.5% of the cases were observed after immunization with DTaP, which might be due to the increased doses. Of the general reactions, 85.1% were fever/redness and swelling/induration. Conclusion: The timely report rate and timely investigation rate of AEFI as well as timely submission rate of investigation table were high in Harbin City. However, the training and supervision on the personnel in grass-root units should be strengthened. Meanwhile, direct network should be established in the units at town level so as to further improve the sensitivity and punctuality of AEFI surveillance system.


Guo S.H.,Beijing Tiantan Biological Products
Zhongguo ji hua mian yi = Chinese journal of vaccines and immunization | Year: 2010

OBJECTIVE: To evaluate the safety and Immunogenicity of the Poliomyelitis vaccine (Human Diploid Cell) in > or =2 month-old children. METHODS: A random, blind and control trial, 1200 healthy children of 2-5 months old in Jiangsu province were administered OPV (HDC) vaccine and control vaccines. The antibody was tested by neutralization test. RESULTS: After 3 doses of the OPV (HDC) vaccine, the systemic reactions were mild. After 1 month of vaccination with 3 doses of the OPV (HDC) vaccine, the immune success rates of I, II, III type were 98.28%, 99.45%, and 95.71% respectively, the GMTs of I, II, III type in susceptible children were 1:1243.72, 1:234.38 and 1:273.10 respectively. CONCLUSIONS: The OPV (HDC) vaccine was safe and immunogenicity for the children > or =2 months old.


Xu N.,Beijing Tiantan Biological Products
Chinese Journal of Biologicals | Year: 2013

Objective: To investigate the relationship of graph pattern of Hansenula polymorpha(HP)-derived hepatitis B surface antigen (HBsAg) purified by hydrophobic interaction chromatography (HIC) to HBsAg and protein contents. Methods: Eight batches of the HP-HBsAg samples for small-scale preparation, five batches of samples for small-scale verification test and five batches of Saccharomyces cerevisae (SC)-derived HBsAg as control were purified by hydropobic chromatography, and determined for protein and HBsAg contents by Lowry method and electrochemiluminescent immunoassay (ECLIA), based on which the recovery rate of HBsAg was calculated. The UV-monitored graph was geometrically divided into several sections, of which the area was integrated by digital planimeter. The main and side peaks of one batch of samples for small-scale verification test were collected for electron microscopy. Results: The mean recovery rate of eight batches of HP-HBsAg samples for small-scale preparation was 70%, while that of five batches for small-scale verification test was 54%. The HIC pattern consisted of breakthrough peak and target (HBsAg) peak, while the target peak appeared as a main peak and a side peak. The pattern of control samples appeared as breakthrough peak and target peak. Further quantitative analysis of the target peak showed that the area ratios of main, side and target peaks were related to those of collected liquid, protein and HBsAg contents. Electron microscopy showed that the sizes of HBsAg particles were even in the collected main peak, while were uneven in the side peak. Conclusion: HIC was effective for purification of HP-derived HBsAg. By comparison of peak area graphed by UV-monitor, the contents of collected liquid, protein and HBsAg were calculated. It provided a reference for further purification of HBsAg.


Objective: To analyze the biochemical properties including the cross-linking degree of disulfide bond between P24 subunits of HBsAg expressed in recombinant Hansenula polymorpha (HP-HBsAg). Methods: The buoyant density of HBsAg was determined by sucrose cushion centrifugation, while the cross-linking degree betweens P24 subunits of HBsAg by SDS-PAGE, and the percents of HBsAg VLPs before and after treatment with thiocyanate by HPLC. The HBsAg expressed in recombinant Saccharomyces cervesiae (SC-HBsAg) was used as control. Results: The buoyant density of HP-HBsAg was (1. 085 ± 0. 014) g/ml, which was similar to that of SC-HBsAg [(1. 090 ± 0. 009) g/ml]. SDS-PAGE demonstrated that the HP-HBsAg untreated with thiocyanate could not enter to the separation gel illustrate, while the untreated SC-HBsAg could. However, after treatment with thiocyanate, neither HP-HBsAg nor SC-HBsAg entered to the separation gel. HPLC demonstrated that, when the mobile phase contained SDS, the percentage of HP-HBsAg VLPs showed no obvious change before and after treatment with thiocyanate, while that of SC-HBsAg VLPs after treatment was higher than that before treatment. However, both the percentages of HP-HBsAg VLPs before and after treatment with thiocyanate were higher than those of SC-HBsAg VLPs. Conclusion: The buoyant density of HP-HBsAg were similar to that of SC-HBsAg. However, the cross-linking degree of disulfide bond between the P24 subunits of HP-HBsAg was higher, while the conjugation was tighter, which needed no treatment with thiocyanate.


Loading Beijing Tiantan Biological Products collaborators
Loading Beijing Tiantan Biological Products collaborators